Trial
NCT05854966
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI); Cornerstone Pharmaceuticals
Condition
Acute Myeloid Leukemia, in Relapse
Intervention
CPI 613
Why stopped
PI decided not to move forward with the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19